Revenue
2018
2019
2020
2021
2022
2023
2024
2025
RIGEL PHARMACEUTICALS INC (RIGL)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M | $4.5M | $20.4M | — | — | — | — | — | — | — |
| Research & development | $33.3M | $23.4M | $24.5M | $60.3M | $65.2M | $60.1M | $52.9M | $46.9M | $46.3M | $63.4M | $62.8M | $67.7M | $75.3M | $78.8M | $69.3M | $64.4M | $90.7M |
| Operating income | $125.5M | $24.2M | −$20.5M | −$55.5M | −$12.5M | −$29.0M | −$69.1M | −$72.7M | −$79.6M | −$69.7M | −$51.7M | −$91.2M | −$89.5M | −$99.4M | −$86.4M | $35.3M | −$112.0M |
| EBITDAderived | $127.9M | $26.4M | −$19.3M | −$54.6M | −$11.3M | −$28.3M | −$68.4M | −$72.1M | −$79.2M | −$68.8M | −$50.3M | −$88.9M | −$86.9M | −$96.9M | −$84.4M | $36.6M | −$110.6M |
| Net income | $367.0M | $17.5M | −$25.1M | −$58.6M | −$17.9M | −$29.7M | −$66.9M | −$70.5M | −$78.0M | −$69.2M | −$51.5M | — | — | — | — | — | — |
| Basic EPSper diluted share | $20.40 | $0.99 | -$1.44 | -$3.44 | -$0.11 | -$0.18 | -$0.40 | -$0.44 | -$0.62 | -$0.73 | -$0.58 | -$1.04 | -$1.02 | -$1.32 | -$1.36 | $0.73 | -$2.73 |
| Diluted EPSper diluted share | $19.48 | $0.99 | -$1.44 | -$3.44 | -$0.11 | -$0.18 | -$0.40 | -$0.44 | -$0.62 | -$0.73 | -$0.58 | -$1.04 | -$1.02 | -$1.32 | -$1.36 | $0.72 | -$2.73 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Ali-Jackson KamilDirector | SellCommon Stock | 2.5K | $35.00 | $87.5K | 10.1K |
| May 26, 2026Form 4 · 10b5-1 | Ali-Jackson KamilDirector | SellCommon Stock | 2.5K | $29.17 | $72.9K | 12.6K |
| Feb 20, 2026Form 4 | MOOS WALTER HDirector | SellCommon Stock | 4.0K | $36.36 | $145.4K | 12.7K |
| Feb 5, 2025Form 4 | Schorno Dean LEVP & Chief Financial Officer | SellCommon Stock | 1.7K | $21.93 | $38.0K | 57.2K |
| Feb 5, 2025Form 4 | Santos David AEVP, Chief Commercial Officer | SellCommon Stock | 1.8K | $21.93 | $39.4K | 51.7K |